Prosensa Holding NV
(NASDAQ : RNA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.41%104.731.1%$1266.22m
GILDGilead Sciences, Inc.
-0.06%72.780.9%$641.23m
AMGNAmgen Inc.
0.02%169.991.1%$478.03m
REGNRegeneron Pharmaceuticals, Inc.
0.22%388.412.7%$359.90m
BIIBBiogen Inc.
-0.70%307.641.2%$347.36m
ALXNAlexion Pharmaceuticals, Inc.
0.68%108.331.9%$268.45m
VRTXVertex Pharmaceuticals Incorporated
-0.28%146.631.9%$232.08m
ALNYAlnylam Pharmaceuticals, Inc
0.55%133.0610.0%$194.23m
INCYIncyte Corporation
-0.16%98.842.5%$178.95m
NKTRNektar Therapeutics
-1.47%49.026.1%$173.99m
ILMNIllumina, Inc.
-0.34%214.613.5%$153.99m
JUNOJuno Therapeutics, Inc.
1.61%61.3013.5%$139.84m
AAgilent Technologies, Inc.
0.44%68.991.5%$132.24m
SRPTSarepta Therapeutics, Inc.
-0.04%56.2016.8%$115.58m
BLUEBluebird Bio, Inc.
0.42%167.9017.2%$114.90m

Company Profile

Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands.